melatonin + valproic acid

Melatonin + valproic acid is a combination of two agents with distinct mechanisms of action. Melatonin is an endogenous neurohormone produced by the pineal gland that regulates circadian rhythms and sleep-wake cycles, acting primarily via MT1 and MT2 receptors. It also exhibits antioxidant and neuroprotective properties. Valproic acid is a small molecule anticonvulsant used in the treatment of epilepsy, bipolar disorder, and migraine prophylaxis; it acts mainly by increasing brain gamma-aminobutyric acid (GABA) levels through inhibition of GABA transaminase, as well as inhibiting histone deacetylases (HDACs), affecting gene expression. Preclinical studies suggest that co-administration may have synergistic effects in certain cancer cell lines (e.g., breast cancer, bladder cancer) due to upregulation of melatonin MT1 receptor expression by valproic acid[2][4]. In animal models, melatonin can counteract memory impairment and hippocampal neurogenesis reduction induced by valproic acid through its antioxidant activity[3][6][8]. This combination has not been approved as a fixed-dose pharmaceutical product but has been studied experimentally for potential benefits in oncology and neuroprotection.

Other names

melatonin and valproic acidmelatonin plus valproic acid